Pfizer is hiring an Alphabet life sciences executive as its first global chief marketing officer, the third major addition to its senior ranks this year.
Drew Panayiotou, chief marketing officer of Alphabet’s life sciences research arm Verily, will join Pfizer on Sept. 19. He will be responsible for building commercial infrastructure including “new innovative engagement channels, tools, and digital solutions,” Pfizer said in an emailed statement. He will report to Angela Hwang, head of Pfizer’s biopharmaceuticals unit.
The announcement comes about six months after two retirements led to a reshuffling of Pfizer’s senior ranks, amid a surge in revenue to record levels from sales of its COVID-19 vaccine and antiviral drug. Pfizer hired William Pao as chief development officer from Roche in February and David Denton as chief financial officer from Lowe’s in April.
Pfizer is familiar with Verily through a partnership it, along with three other pharmas, signed with the technology company in 2019 to tap its data tools for clinical studies.
Panayiotou was also the first chief marketing officer at Verily. He has more than 30 years experience in marketing, previously working at Johnson & Johnson, Coca-Cola and Disney, among others. At Pfizer, he joins a company whose business dwarfs most others in the pharma sector, after its first-half revenues surged by 60% and are on track to reach about $100 billion for the first time.
“Drew’s insights and diverse thinking will help us elevate the cutting-edge customer channels, skills and capabilities we need to deliver” new medicines to patients, Hwang said in a LinkedIn post.
By Christopher Newman
Source: biopharmadive.com
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
